Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Pfizer ends bid for OTC Lipitor

Pfizer ends bid for OTC Lipitor

The drugmaker told investors that the actual-use trial failed to meet the primary objectives.

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

MMC hires first CMO

The integrated agency's pharmaceutical business now brings in half its billings.

Five things for pharma marketers to know: Monday, July 27

Five things for pharma marketers to know: Monday, July 27

Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend

Therapeutic Focus: Oncology

Therapeutic Focus: Oncology

Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment

FDA approves first PCSK9 inhibitor

FDA approves first PCSK9 inhibitor

The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.

The MM&M Weekly News Quiz: July 24

The MM&M Weekly News Quiz: July 24

Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 24

Five things for pharma marketers to know: Friday, July 24

UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth

BMS US sales are down, despite growing Opdivo adoption

BMS US sales are down, despite growing Opdivo adoption

Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.

Five things for pharma marketers to know: Thursday, July 23

Five things for pharma marketers to know: Thursday, July 23

Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.

Praluent's FDA review looms, but questions persist

Praluent's FDA review looms, but questions persist

A next-generation cardiovascular drug is expected to be approved this week, but concerns abound about who will take it—and how much it will cost.

Five things for pharma marketers to know: Wednesday, July 22

Five things for pharma marketers to know: Wednesday, July 22

Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed

Orchestrating Key Stakeholder Engagement for Launch Success

Orchestrating Key Stakeholder Engagement for Launch Success

The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.

Allergan debuts #ActuallySheCan campaign

Allergan debuts #ActuallySheCan campaign

The new campaign seeks to connect with millennial women.

Five things for pharma marketers to know: Tuesday, July 21

Five things for pharma marketers to know: Tuesday, July 21

Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter

CMS updates CME guidance

CMS updates CME guidance

New rules will require manufacturers to report some indirect payments made to physicians for CME activities.

The FDA seeks comments on DTC ad perception

The agency plans to research extrinsic factors that influence the way a patient perceives a drug.

Five things for pharma marketers to know: Monday, July 20

Five things for pharma marketers to know: Monday, July 20

Robert Ingram sounds off on drug transparency laws in WSJ op-ed; patients with certain forms of leukemia went into complete remission after taking Amgen's cancer drug; Eli Lilly's future in Alzheimer's disease pinned to new data surfacing this week

Five things for pharma marketers to know: Friday, July 17

Five things for pharma marketers to know: Friday, July 17

Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker

NORD and University of Maryland partner for rare-disease research training

The National Organization for Rare Disorders and the University of Maryland will develop a training program to help caregivers and patients participate in research.

Patients expect pharma will boost engagement

Patients expect pharma will boost engagement

The pharma business needs to take engagement far more seriously than it has in the past. At the same time, there are signs that the industry is finally acting with more urgency and even transparency.

Pricing pressure drives pharma collaborations, report says

Pricing pressure drives pharma collaborations, report says

The backlash to expensive specialty medications has forced the drug industry to partner up to prove the benefits of their medicines in the real world, according to a PwC analysis.

New Sanofi CEO reorganizes company

The restructuring is expected to simplify the drugmaker's organization.

Five things for pharma marketers to know: Wednesday, July 15

Five things for pharma marketers to know: Wednesday, July 15

Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands

J&J prepares to defend Remicade market share

J&J prepares to defend Remicade market share

Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.

Private equity firm acquires CME provider

Vesey Street Capital Partners acquired Atlanta-based CME provider Imedex.

Five things for pharma marketers to know: Tuesday, July 14

Five things for pharma marketers to know: Tuesday, July 14

The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices

More than 400 drugs in development for neurological disorders

PhRMA and the Epilepsy Foundation said 50-million Americans are affected by disorders such as Alzheimer's disease and multiple sclerosis.

Five things for pharma marketers to know: Monday, July 13

Five things for pharma marketers to know: Monday, July 13

Harvoni is now prescribed more than Sovaldi; healthcare group says new hepatitis-C drugs are cost-effective; Roche antibody shrank tumors in certain bladder-cancer patients

Five things for pharma marketers to know: Friday, July 10

Five things for pharma marketers to know: Friday, July 10

21st Century Cures legislation passes the House; Novartis's heart-failure drug may launch with "beyond the pill" services; Purdue and GSK are working on using Apple's ResearchKit; the FDA issues warning letter on co-pay card

House expected to vote on 21st Century Cures

House expected to vote on 21st Century Cures

The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.

Five things for pharma marketers to know: Thursday, July 9

Five things for pharma marketers to know: Thursday, July 9

Pregnant women taking Prozac or Paxil have higher risks of birth defects; study finds J&J's experimental psoriasis drug works better than Humira; AstraZeneca divests global rights to Entocort

AdComm Preview: Eli Lilly's lung-cancer drug

AdComm Preview: Eli Lilly's lung-cancer drug

An FDA advisory panel will discuss the fate of Lilly's investigational lung-cancer antibody, necitumumab, which improved overall survival incrementally but also had one late-stage trial halted due to an "imbalanced number of deaths" attributed to blood clots.

Novartis bets on demand for new heart-failure drug Entresto

Novartis bets on demand for new heart-failure drug Entresto

The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.

Five things for pharma marketers to know: Wednesday, July 8

Five things for pharma marketers to know: Wednesday, July 8

CDC report finds prescription painkiller abuse contributed to an increase in heroin use; Novartis heart-failure drug gets FDA approval; Isis Pharmaceuticals obtains orphan-drug designation for volanesorsen

Insurance trade group says new HCV drugs could cost California billions

An analysis by a state insurance trade group forecast that paying for new HCV treatments could cost taxpayers billions of dollars.

Five things for pharma marketers to know: Tuesday, July 7

Five things for pharma marketers to know: Tuesday, July 7

Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher

Curious if you're a finalist in the MM&M Awards? Find out now

Curious if you're a finalist in the MM&M Awards? Find out now

The finalists in each of the 32 categories for this year's MM&M Awards are revealed here.

Vertex's Orkambi nabs FDA approval but may face payer backlash

Vertex's Orkambi nabs FDA approval but may face payer backlash

The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.

Five things for pharma marketers to know: Monday, July 6

Five things for pharma marketers to know: Monday, July 6

Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company

Five things for pharma marketers to know: Thursday, July 2

Five things for pharma marketers to know: Thursday, July 2

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs

Sermo expands to Canada in global expansion

Sermo expands to Canada in global expansion

The social networking site for doctors also plans to expand to its first Spanish-speaking country next month.

Pharmacy groups urge consistent naming of biosimilars

Pharmacy groups urge consistent naming of biosimilars

The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.

Five things for pharma marketers to know: Wednesday, July 1

Five things for pharma marketers to know: Wednesday, July 1

Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME

Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Manufacturers pay $6.5 billion to healthcare providers in 2014

Manufacturers pay $6.5 billion to healthcare providers in 2014

The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Five things for pharma marketers to know: Friday, June 26

Five things for pharma marketers to know: Friday, June 26

Supreme Court affirmed the legality of the Affordable Care Act for a second time on Thursday

Five things for pharma marketers to know: Wednesday, June 24

Five things for pharma marketers to know: Wednesday, June 24

AbbVie says curative effects hold whether Viekira Pak used with or without ribavirin; House Republicans vote to eliminate IPAB; analyst sets high price target for Alexion.

Five things for pharma marketers to know: Tuesday, June 23

Five things for pharma marketers to know: Tuesday, June 23

Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill

Studies show blood thinner antidotes work

Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.

Five things for pharma marketers to know: Monday, June 22

Five things for pharma marketers to know: Monday, June 22

AstraZeneca, DigitasLBI New York take top prize in pharma category at Cannes Lions Health; Teva buys a stake in Mylan; Shire tops pharma reputation survey.

Grand Prix drought ends, but questions persist

Grand Prix drought ends, but questions persist

The inspirational value is clear for Lions Health attendees, but there is still confusion about what good looks like for branded pharma campaigns, and how the US fits in.

Pharma at Cannes: C'est la Vie

Pharma at Cannes: C'est la Vie

It's not only a venue to gain creative inspiration, but a good place to scout talent, and there are no lack of strategic meetings underway in Cannes.

Novartis exec: Pharma culture can be stumbling block to creativity

Novartis exec: Pharma culture can be stumbling block to creativity

It's not always regulation or concerns about legal risks. Sometimes, a drugmaker's internal conservative culture is the biggest hurdle to overcome.

AstraZeneca wins Pharma Grand Prix at Cannes

AstraZeneca wins Pharma Grand Prix at Cannes

AstraZeneca's "Take it from a Fish" took the top prize.

Five things for pharma marketers to know: Friday, June 19

Five things for pharma marketers to know: Friday, June 19

Teva loses Copaxone patent suit; Oncologists at Memorial Sloan Kettering Cancer Center developed cancer drug cost calculator; Bayer will invest $4.5 billion in R&D in the coming year.

19 US entries shortlisted at Lions Health

19 US entries shortlisted at Lions Health

The Lions Health award winners will be announced later Friday at an event in Cannes, France.

Doximity expands professional reach

Its alliance with the Society of Hospital Medicine will expand the network's reach among medical professionals.

Takeda revamps commercial org to synch with R&D

Takeda revamps commercial org to synch with R&D

The Japan-based drugmaker recast its global organization in hopes of ensuring that emerging molecules make a smoother transition to market.

EY launches health innovation incubator

The effort is part of the consultancy's Startup Challenge that pairs health neophytes with mentors.

Five things for pharma marketers to know: Thursday, June 18

Five things for pharma marketers to know: Thursday, June 18

Merck settles a marketing lawsuit for $5.9 million; CVS plans to create diagnostic apps; a survey shows advertising agencies plan to keep head count steady for the rest of the year

Lilly moves to bolster its oncology pipeline

Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute signed on to help the drugmaker develop cancer treatments.

Drug pricing drives debates at BIO convention

Drug pricing drives debates at BIO convention

Drugmakers, experts discuss strategies to cope with costly new drugs.

Five things for pharma marketers to know: Wednesday, June 17

Five things for pharma marketers to know: Wednesday, June 17

Allergan acquires double-chin treatment manufacturer, Kythera, for $2.1 billion; Valeant eyes acquisition of Egyptian drugmaker; worldwide drug sales could reach $1 trillion by 2020

Study shows pharma compensates genders differently

Study shows pharma compensates genders differently

A dive into financial relationships between industry and doctors showed women receive less money for research, education and speaking than men.

Clinton tells pharma to explain drug prices

Clinton tells pharma to explain drug prices

Speakers at Klick Health's event criticized, lauded the role of technology in healthcare.

Bayer and Johns Hopkins University ink eye-disease research collaboration

The drugmaker and university will work together to develop new treatments for eye-related diseases like age-related macular degeneration.

Five things for pharma marketers to know: Tuesday, June 16

Five things for pharma marketers to know: Tuesday, June 16

Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs

Amicus briefs pile up in Amarin lawsuit

The Medical Information Working Group and the Washington Legal Foundation filed briefs in support of Amarin.

Survey shows doctors ready for PCSK9s

Survey shows doctors ready for PCSK9s

Cardiologists are more likely to prescribe the experimental drugs than are primary-care physicians.

Five things for pharma marketers to know: Monday, June 15

Five things for pharma marketers to know: Monday, June 15

CVS Health to buy Target's pharmacy business; experimental gene therapy improves condition of teen with sickle-cell disease; PatientsLikeMe partners with the FDA to improve postmarket surveillance

Five things for pharma marketers to know: Friday, June 12

Five things for pharma marketers to know: Friday, June 12

PhRMA files amicus brief in support of Amarin's off-label lawsuit; Public Citizen argues FDA wrongly expanded indication for Hetlioz; FDA panel recommends GSK's new asthma treatment for approval

Amarin lawsuit about more than fish oil

Amarin lawsuit about more than fish oil

An FDA letter says there was no need to go to court but experts tell MM&M this lawsuit highlights an issue that is bigger than a single pill.

Public health officials to distribute Truvada in fight against HIV

Los Angeles County voted in favor of adding the drug to the public health program's repertoire in fighting HIV and AIDS.

Five things for pharma marketers to know: Thursday, June 11

Five things for pharma marketers to know: Thursday, June 11

Amgen's PCSK9 inhibitor is the second in its class to get an FDA panel endorsement; a new drug could threaten Shire's hold on a rare-disease category; a study shows pharma invests less in Hispanic audiences than in other groups

Pioneering info portal for doctors turns 20

Pioneering info portal for doctors turns 20

Medscape marked its 20th anniversary with a reunion this week that attracted staffers from the portal's earliest days.

Pfizer's "Get Old" campaign gets youthful

Pfizer's "Get Old" campaign gets youthful

The three-year-old campaign's youthful tone evolves as its audience ages.

Roche sclerosis drug granted Breakthrough Therapy status

Roche's Actemra is already approved for three forms of arthritis.

Five things for pharma marketers to know: Wednesday, June 10

Five things for pharma marketers to know: Wednesday, June 10

FDA panel recommends Sanofi/Regeneron's PCSK9 inhibitor for approval; Merck and Samsung collaboration says their rheumatoid arthritis biosimilars are equivalent to the biologic versions; Bayer offloads its diabetes-care business

Study: 10 medications will cost US $50 billion over 10 years

Study: 10 medications will cost US $50 billion over 10 years

An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.

Lions Health entries increase by 30% in 2015

A quarter of this year's 1,862 entries are in the pharma category.

GSK asthma medication to go before FDA panel Thursday

GSK asthma medication to go before FDA panel Thursday

There has been little talk about mepolizumab but an approval would fill out GSK's flagging respiratory category.

Sanofi will resubmit lixisenatide to FDA

The drugmaker's once-daily diabetes treatment, lixisenatide, will be sent back to US regulators after Sanofi pulled the submission in 2013 to finish a cardiovascular outcomes trial.

Five things for pharma marketers to know: Tuesday, June 9

Five things for pharma marketers to know: Tuesday, June 9

Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids

PCSK9 adcomm preview: what's at stake

PCSK9 adcomm preview: what's at stake

An FDA advisory committee will sound off on the future of cholesterol-lowering treatments this week, discussing if Sanofi/Regeneron's Praluent and Amgen's Repatha warrant marketing approval.

Everyday Health names new EVP

Jed Savage replaces Scott Wolf.

Lilly says peglispro is superior to Sanofi's Lantus

Concerns persist regarding the drug's impact on liver enzymes and fat.

Five things for pharma marketers to know: Monday, June 8

Five things for pharma marketers to know: Monday, June 8

Novartis CEO says pharma must regulate itself; Shire reportedly is in talks to buy biotech Actelion; Lilly insulin outperforms Lantus although safety concerns remain

Five things for pharma marketers to know: Friday, June 5

Five things for pharma marketers to know: Friday, June 5

FDA panel recommends approval of female Viagra; FDA says that Sanofi's and Regeneron's PCSK9 inhibitor lowers LDL; GSK cuts 350 jobs

DTC expected to propel Afrezza awareness, not necessarily sales

DTC expected to propel Afrezza awareness, not necessarily sales

Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.

A Patient Journey Isn't the Solution to Pharma Marketing—It's the Beginning

A Patient Journey Isn't the Solution to Pharma Marketing—It's the Beginning

We need to view the patient journey as a starting place for much deeper analysis.

FDA grants Breakthrough status to Niemann-Pick drug

Genzyme's experimental enzyme-replacement therapy olipudase alfa is being investigated for the Type B form of the condition.

Five things for pharma marketers to know, Thursday, June 4

Five things for pharma marketers to know, Thursday, June 4

Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting

Study: Patients with marketplace health plans spend less on medications

Study: Patients with marketplace health plans spend less on medications

Employer-insured enrollees spend more on prescriptions than health-insurance exchange enrollees, but the groups spend the same amount of money when it comes to specialty medications, a study shows.

Five things for pharma marketers to know: Wednesday, June 3

Five things for pharma marketers to know: Wednesday, June 3

Teva is planning to up its stake in Mylan prior to a possible legal challenge; Perrigo acquires GSK OTC portfolio; Express Scripts considers creative ways to drive down drug costs

Patient advocacy groups say pharma needs to be a better partner

Patient advocacy groups say pharma needs to be a better partner

An inVentiv Health study indicates patient groups want more say in drug development and patient support.

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.